Clinical trial

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

NCT07533565

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Mirabegron 100 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Mirabegron 50mg Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record mirabegron 25 mg Normalized identity: mirabegron 25 MGView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Montelukast 10 mg Normalized identity: montelukast 10 MGView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention montelukast (5mg QD) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention montelukast 4 mg granule Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-07-01

PhasePHASE4

Conditions

Cirrhosisverified · MONDO: cirrhosis of liver

Asthmaverified · MONDO: asthma

Interventions

Mirabegron 100 mgDRUG

Mirabegron 50mgDRUG

mirabegron 25 mgDRUG · verified · RxNorm: mirabegron 25 MG

Montelukast 10 mgDRUG · verified · RxNorm: montelukast 10 MG

montelukast (5mg QD)DRUG

montelukast 4 mg granuleDRUG

Sponsors & collaborators

Kafrelsheikh Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07533565 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.